CSL Behring AssuranceSM

CareZ assures access to treatment

Our assurance program helps people who rely on Zemaira continue to receive treatment, even if they experience a lapse in their third-party, private health insurance. By providing Zemaira to qualified people in their time of need, we can offer an added level of security for people who rely on augmentation therapy.

How it works

CSL Behring Assurance allows you to build up a reserve of complimentary Zemaira that you can easily access if you have a gap in coverage. It's a protection plan that costs you nothing and only requires that you complete a quick and easy enrollment process to start gaining its benefits.

  • Anyone who uses Zemaira and has third-party, private health insurance (for example, an HMO, PPO, or fee-for-service plan) can enroll in CSL Behring Assurance*
To speak with a CareZ Case Manager and learn more about CSL Behring Assurance, call 1-800-415-2167.

To enroll or learn more, visit www.cslbehringassurance.com

"Peace of mind is something that does not come very often or easily for families affected by Alpha-1. Now with CSL Behring Assurance, families can have a new sense of security and greater peace of mind knowing that they can continue to have access to their treatment even if they lose their third-party, private insurance."

John Walsh, President and CEO, Alpha-1 Foundation

* CSL Behring Assurance is open to individuals enrolled in Medicare Managed Care (for example, a Medicare + Choice or Medicare Advantage plan; not Medicare Part A and Part B). Both Medicare Managed Care and Medicaid Managed Care plans are offered through private companies that contract through the government.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Do you want to continue?

No Yes